Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial

Cited by (1,000)

Items 601–700 of 1,000

1. Will Evidence-based Medicine Survive the COVID-19 Pandemic?
   Ary Serpa Neto, Carol Lynette Hodgson · 2020 · Annals of the American Thoracic Society
2. Hydroxychloroquine in Hospitalized Patients with Covid-19
   Alexis Lacout, Christian Perronne, Valere Lounnas · 2021 · New England Journal of Medicine
3. Retraction Note: Safety and efficacy of favipiravir versus hydroxychloroquine in management of COVID-19: A randomised controlled trial
   Hany Mansour Dabbous, Manal Hamdy El-Sayed, Gihan El Assal, Hesham A. Elghazaly, Fatma Soliman Elsayed Ebeid, Ahmed Fouad Sherief, Maha Elgaafary, Ehab Fawzy, Sahar Mohamed Hassany, Ahmed Radwan Riad et al. · 2021 · Scientific Reports · Retracted
4. Importance of sample size determination for randomized controlled clinical trials for coronavirus disease 2019 antiviral therapies
   Getu Zhaori · 2024 · Pediatric Investigation
5. Emerging therapeutics in the management of COVID-19
   Asim Kichloo, Michael Stanley Albosta, Akshay Kumar, Michael M. Aljadah, Mohamed Mohamed, Zain El‐amir, Farah Wani, Shakeel Muhammad Jamal, Jagmeet Singh, Akif Ahmed Kichloo · 2021 · World Journal of Virology
6. Core shell stationary phase for a novel separation of some COVID-19 used drugs by UPLC-MS/MS Method: Study of grapefruit consumption impact on their pharmacokinetics in rats
   Sally Tarek Mahmoud, Marwa A. Moffid, Rawda M. Sayed, Eman A. Mostafa · 2022 · Microchemical Journal
7. A systematic review of acute and emergency care interventions for adolescents and adults with severe acute respiratory infections including COVID-19 in low- and middle-income countries
   Stephanie Chow Garbern, Pryanka Relan, Gerard Michael O’Reilly, Corey B Bills, Megan L. Schultz, Indi Trehan, Sean M Kivlehan, Torben Kim Becker · 2022 · Journal of Global Health
8. Hydroxychloroquine for treatment of COVID-19 patients: a systematic review and meta-analysis of randomized controlled trials
   Vinícius Ynoe de Moraes, Alexandre Rodrigues Marra, Leandro Luongo Matos, Ary Serpa Neto, Luiz Vicente Rizzo, Miguel Cendoroglo, Mário Lenza · 2022 · Einstein (São Paulo)
9. Investigational Therapies for the Treatment of COVID-19: Updates from Ongoing Clinical Trials
   Alexandra J Abrams-Downey, Joseph Saabiye, Monica M. Vidaurrazaga · 2020 · European Urology Focus
10. ANÁLISE BIBLIOMÉTRICA DA PRODUÇÃO BRASILEIRA SOBRE A COVID-19
    Wilton Nascimento Figueredo, Tássia Teles Santana de Macêdo, Gustavo Marques Porto Cardoso, Elionara Teixeira Boa Sorte Fernandes · 2020 · Revista Baiana de Enfermagem‏
11. Statistical design of Phase II/III clinical trials for testing therapeutic interventions in COVID-19 patients
    Shesh Nath Rai, Chen Qian, Jianmin Pan, Anand K. Seth, Deo Kumar Srivastava, Aruni Bhatnagar · 2020 · BMC Medical Research Methodology
12. An overview on the use of antivirals for the treatment of patients with COVID19 disease
    Maricar F. Malinis, Dayna S. McManus, Matthew Davis, Jeffrey E. Topal · 2020 · Expert Opinion on Investigational Drugs
13. The Potential Benefit of Beta-Blockers for the Management of COVID-19 Protocol Therapy-Induced QT Prolongation: A Literature Review
    Teuku Heriansyah, Indah Nur Chomsy, Lyra Febrianda, Tjut Farahiya Hadi, Titin Andri Wihastuti · 2020 · Scientia Pharmaceutica
14. Acute kidney injury in COVID 19 – an update on pathophysiology and management modalities
    Manoj Khokhar, Purvi Purohit, Dipayan Roy, Sojit Tomo, Ashita Gadwal, Anupama Modi, Mithu Banerjee, Praveen Sharma · 2020 · Archives of Physiology and Biochemistry
15. The therapeutic effect and safety of the drugs for COVID-19
    Rong Qiu, Jingwei Li, Yuxuan Xiao, Ziyi Gao, Yihang Weng, Qiran Zhang, Chengdi Wang, Hanlin Gong, Weimin Li · 2021 · Medicine
16. Health care of the elderly during Covid-19 pandemic—All a family physician should know
    Kamal Bandhu Klanidhi, M Bhavesh, Piyush Ranjan, Avinash Chakrawarty, Shailendra S. Bhadouria · 2021 · Journal of Family Medicine and Primary Care
17. Adverse Effects Associated With the Use of Antimalarials During The COVID-19 Pandemic in a Tertiary Care Center in Mexico City
    Oscar Arturo Lozano-Cruz, José Víctor Jiménez, Antonio Olivas‐Martínez, Edgar Ortíz‐Brizuela, José Luis Cárdenas-Fragoso, Daniel Azamar‐Llamas, Sergio Rodríguez‐Rodríguez, Jorge Oseguera-Moguel, Joel Dorantes-García, Clemente Barrón-Magdaleno et al. · 2021 · Frontiers in Pharmacology
18. Translational Modeling of Chloroquine and Hydroxychloroquine Dosimetry in Human Airways for Treating Viral Respiratory Infections
    Aditya Reddy Kolli, Florian Calvino-Martin, Julia Hoeng · 2022 · Pharmaceutical Research
19. Anti-cytokine therapy in novel coronavirus disease (COVID-19) – the first administration of tocilizumab in Hungary at a department of infectology
    Botond Lakatos, László Gopcsa, Enikő Gondos, Alexandra Riczu, Zsuzsa Várnai, Eva Livia Nagy, Eszter Molnár, Gabriella Bekő, Ilona Bobek, Peter Pal Remenyi et al. · 2020 · PubMed
20. A multivariate analysis on spatiotemporal evolution of Covid-19 in Brazil
    Márcio Luis Ferreira Nascimento · 2020 · Infectious Disease Modelling
21. Combating the Progression of Novel Coronavirus SARS-CoV-2 Infectious Disease: Current State and Future Prospects in Molecular Diagnostics and Drug Discovery
    Arbind Kumar, Aashish Sharma, Narendra Vijay Tirpude, Sharad Thakur, Sanjay Kumar · 2021 · Current Molecular Medicine
22. Hydroxychloroquine alone or in combination with azithromycin to prevent major clinical events in hospitalised patients with coronavirus infection (COVID-19): rationale and design of a randomised, controlled clinical trial
    Alexandre Biasi Cavalcanti, Fernando Godinho Zampieri, Luciani CP Azevedo, Régis Goulart Rosa, Álvaro Avezum, Viviane Cordeiro Veiga, Renato D. Lópes, Leticia Barbosa Kawano-Dourado, Lucas Petri Damiani, Adriano José Pereira et al. · 2020 · medRxiv
23. Extracorporeal Membrane Oxygenation for COVID-19
    Zachary Sanford, Ronson J. Madathil, Kristopher B. Deatrick, Ali Tabatabai, Jay A. Menaker, Samuel M. Galvagno, Michael A. Mazzeffi, Joseph Rabin, Mehrdad Ghoreishi, Raymond P. Rector et al. · 2020 · Innovations Technology and Techniques in Cardiothoracic and Vascular Surgery
24. Insufficient Fibrinolysis in COVID-19: A Systematic Review of Thrombolysis Based on Meta-Analysis and Meta-Regression
    Hong‐Long Ji, Zhenlei Su, Runzhen Zhao, Andrey A. Komissarov, Guohua Yi, Shan‐Lu Liu, Steven Idell, Michael A. Matthay · 2020 · medRxiv
25. Regulation of miRNA in Cytokine Storm (CS) of COVID‐19 and Other Viral Infection: An Exhaustive Review
    Chiranjib Chakraborty, Manojit Bhattacharya, Arpita Das, Abinit Saha · 2025 · Reviews in Medical Virology
26. Effects of Short-Term Hydroxychloroquine Plus Moxifloxacin Therapy on Corrected QT Interval and Tp-e Interval in Patients With COVID-19
    Abdülmecit Afşin, Kenan Ecemiş, Ramazan Asoğlu · 2020 · Journal of Clinical Medicine Research
27. Effect of Chloroquine and Hydroxychloroquine on COVID-19 Virological Outcomes: An Updated Meta-Analysis
    Rashmi Ranjan Das, Bijayini Behera, Baijayantimala Mishra, Sushree Samiksha Naik · 2020 · Indian Journal of Medical Microbiology
28. Chloroquine, the Coronavirus Crisis, and Neurodegeneration: A Perspective
    Giona Pedrioli, Rickie Patani, Paolo Paganetti · 2020 · Frontiers in Neurology
29. Comparison of Liver Safety of Favipiravir and Hydroxychloroquine in COVID-19 Treatment
    Feyza İzci Çetinkaya, Hatice Karagöz, Acibadem Kayseri Hastanesi, Ic Hastaliklari Klinigi, Kayseri, Turkiye, Orhan Yildiz · 2020 · Klimik Dergisi/Klimik Journal
30. The effect of Psidium guajava Leaves’ extract for mild and asymptomatic corona virus Disease-19
    Fredia Heppy, Roza Mulyana, Nur Afrainin Syah, Raymond R. Tjandrawinata · 2023 · Saudi Pharmaceutical Journal
31. A combination of logical judging circuit and water-resistant ultrathin film PEDOT: PSS electrode for noninvasive ECG measurement
    Kewei Song, Kayo Hirose, Kioto Niitsu, Tsubasa Sui, Hiroto Kojima, Toshinori Fujie, Shinjiro Umezu · 2024 · Discover Nano
32. Pharmacotherapy in COVID 19: Potential Impact of Targeting the Complement System
    Courtney M. Barkoff, Shaker A. Mousa · 2020 · Biomedicines
33. No clinical benefit in mortality associated with hydroxychloroquine treatment in patients with COVID-19
    Kenneth Sands, Richard P. Wenzel, Laura E. McLean, Kimberly M. Korwek, Jonathon D. Roach, Karla M. Miller, Russell E. Poland, L. Hayley Burgess, Edmund S. Jackson, Jonathan B. Perlin · 2021 · International Journal of Infectious Diseases
34. COVID ‐19 and the generation of novel scientific knowledge: Research questions and study designs
    Lucie O. M. Perillat, Brian S. Baigrie · 2021 · Journal of Evaluation in Clinical Practice
35. Can Anti-Parasitic Drugs Help Control COVID-19?
    Yasin Panahi, Masoomeh Dadkhah, Sahand Talei, Zahra Gharari, Vahid Asghariazar, Arash Abdolmaleki, Somayeh Matin, Soheila Molaei · 2022 · Future Virology
36. Pharmacometric and Electrocardiographic Evaluation of Chloroquine and Azithromycin in Healthy Volunteers
    Palang Chotsiri, Joel Tärning, Richard M. Hoglund, James A Watson, Nicholas John White · 2022 · Clinical Pharmacology & Therapeutics
37. Capturing the Complexity of COVID-19 Research: Trend Analysis in the First Two Years of the Pandemic Using a Bayesian Probabilistic Model and Machine Learning Tools
    Javier de la Hoz-M, Susana Mendes, María José Fernández Gómez, Yolanda González Silva · 2022 · Computation
38. Quality Assessment of the Chinese Clinical Trial Protocols Regarding Treatments for Coronavirus Disease 2019
    Jiaxing Zhang, Yiling Lu, Joey Sum-Wing Kwong, Xiaosi Li, Wenyi Zheng, Rui He · 2020 · Frontiers in Pharmacology
39. Treatment Options for Coronavirus Disease 2019 in Patients With Reduced or Absent Kidney Function
    Hilary Miller‐Handley, Keith M. Luckett, Amit Govil · 2020 · Advances in Chronic Kidney Disease
40. The Fight against COVID-19 on the Multi-Protease Front and Surroundings: Could an Early Therapeutic Approach with Repositioning Drugs Prevent the Disease Severity?
    Annamaria Vianello, Serena Del Turco, Serena Babboni, Beatrice Silvestrini, Rosetta Ragusa, Chiara Caselli, Luca Melani, Luca Fanucci, Giuseppina Basta · 2021 · Biomedicines
41. Modelling of Systemic versus Pulmonary Chloroquine Exposure in Man for COVID-19 Dose Selection
    Ghaith Aljayyoussi, Rajith K. R. Rajoli, Henry E. Pertinez, Shaun H. Pennington, Weiqian David Hong, Paul M. O’Neill, Andrew Owen, Stephen Andrew Ward, Giancarlo A. Biagini · 2020 · medRxiv
42. Rethinking antiviral effects for COVID-19 in clinical studies: early initiation is key to successful treatment
    Shoya Iwanami, Keisuke Ejima, Kwang Su Kim, Koji Noshita, Yasuhisa Fujita, Taiga Miyazaki, Shigeru Kohno, Yoshitsugu Miyazaki, Shimpei Morimoto, Shinji Nakaoka et al. · 2020 · medRxiv
43. Risk of QTc prolongation with Chloroquine/Hyroxychloroquine and Azithromycin treatment for COVID‐19: Quantification and precautions for a busy clinician
    Zeeshan Mansuri, Mahwish Adnan, Fatima Bilal Motiwala, Muhammad Khalid Zafar, Taranjeet S. Jolly, Shailesh Bobby Jain · 2020 · Journal of Arrhythmia
44. It is time to drop hydroxychloroquine from our COVID-19 armamentarium
    Tarek Kashour, Imad M. Tleyjeh · 2020 · Medical Hypotheses
45. Challenges in Repurposing Drugs in COVID-19 Pandemic. Debating on Potential New Refinements
    Giorgio Frega, Andrea Palloni, Giuseppe Di Pasquale, Gioconda Saccoccio, Alessandro Rizzo, Elisabetta Poluzzi, Primiano Iannone, Giovanni Brandi · 2020 · Frontiers in Pharmacology
46. Repurposed pharmacological agents for the potential treatment of COVID-19: a literature review
    Alina Kröker, Madara Tirzīte · 2021 · Respiratory Research
47. The effect of oseltamivir use in critically ill patients with COVID-19: A multicenter propensity score-matched study
    Ohoud A. Aljuhani, Ghazwa B. Korayem, Ali Faris Altebainawi, Meshal Saud Alotaibi, Noura A. Alrakban, Ragia H. Ghoneim, Ramesh Kumar Vishwakarma, Abdulrahman I. Al Shaya, Shmeylan A. Al Harbi, Jawaher Abdullah Gramish et al. · 2023 · Saudi Pharmaceutical Journal
48. Cardiovascular Considerations for the Internist and Hospitalist in the COVID-19 Era
    Michael R. Massoomi, R. David Anderson, Mustafa Mohammed Ahmed, Osama Dasa, Philip George, William M. Miles, Juan M. Aranda, Carl J. Pepine · 2020 · The American Journal of Medicine
49. Predictive factors for cardiac conduction abnormalities with hydroxychloroquine-containing combinations for COVID-19
    Sergio Padilla, Guillermo Telenti, Lucía Guillén, José Alberto García, Javier García‐Abellán, Carolina Ding, Antonia Mora, Eduardo García-Pachón, Félix Gutiérrez, Mar Masiá · 2020 · International Journal of Antimicrobial Agents
50. Therapeutic Options Against the New Coronavirus: Updated Clinical and Laboratory Evidences
    Amélia Carolina Lopes Fernandes, Adson José Martins Vale, Fausto Pierdoná Gúzen, Francisco Irochima Pinheiro, Ricardo Ney Cobucci, Eduardo Pereira de Azevedo · 2020 · Frontiers in Medicine
51. Mitigating arrhythmia risk in Hydroxychloroquine and Azithromycin treated COVID-19 patients using arrhythmia risk management plan
    Kazimieras Maneikis, Ugnė Ringelevičiūtė, Justinas Bacevičius, Egle Dieninyte-Misiune, Emilija Burokaitė, Gintarė Kazbaraitė, Marta Monika Janusaite, Austėja Dapkevičiūtė, Andrius Žučenka, Valdas Pečeliūnas et al. · 2020 · IJC Heart & Vasculature
52. COVID-19, hydroxychloroquine and sudden cardiac death: implications for clinical practice in patients with rheumatic diseases
    Hussain Ahmed Raza, Javeria Tariq, Vikas Agarwal, Latika Gupta · 2021 · Rheumatology International
53. Pharmacotherapeutics of SARS-CoV-2 Infections
    Bhavesh D. Kevadiya, Jatin Machhi, J. Herskovitz, Maxim D. Oleynikov, Wilson R. Blomberg, N. Bajwa, Dhruvkumar Soni, Srijanee Das, M. Hasan, Milankumar Patel et al. · 2021 · Journal of Neuroimmune Pharmacology
54. Adverse drug event risk assessment by the virtual addition of COVID‐19 repurposed drugs to Medicare and commercially insured patients’ drug regimens: A drug safety simulation study
    Matt K. Smith, Ravil Bikmetov, Sweilem B. Al Rihani, Malavika Deodhar, Matthew J. Hafermann, Pamela Dow, Jacques Turgeon, Véronique Michaud · 2021 · Clinical and Translational Science
55. What we learned in the past year in managing our COVID-19 patients in intensive care units?
    Nitesh Jain, Rahul Kashyap, Salim Surani · 2021 · World Journal of Critical Care Medicine
56. A randomized, open-label, multicentre, comparative study of therapeutic efficacy, safety, and tolerability of BNO 1030 extract, containing marshmallow root, chamomile flowers, horsetail herb, walnut leaves, yarrow herb, oak bark, dandelion herb, in the treatment of mild forms of COVID-19
    Vasyl Popovych, Ivana V. Koshel, Yulia Haman, Vitalii Leshak, Oleksandr Malofiichuk, Natalia Kapustina, Ihor Shevaga, Olha Shevaga, Tetiana Kunytska · 2021 · Clinical Phytoscience
57. Hydroxychloroquine/chloroquine and the risk of acute kidney injury in COVID-19 patients: a systematic review and meta-analysis
    Zheng-Ming Liao, Zhong-Min Zhang, Qi Liu · 2022 · Renal Failure
58. Remdesivir-induced bradycardia in patients hospitalized with SARS-CoV2 infection: a possible vagally-mediated mechanism
    Annalisa Filtz, Angelica Carandina, Annalaura Fasiello, Laura Barbetta, Rosa Lombardi, Felice Cinque, Giulia Rizzi, Elisa Ceriani, Ludovico Furlan, Chiara Bellocchi et al. · 2022 · Internal and Emergency Medicine
59. Niclosamide as a chemical probe for analyzing SARS-CoV-2 modulation of host cell lipid metabolism
    Timothy J. Garrett, Heather G. Coatsworth, Iqbal Mahmud, Timothy Hamerly, Caroline J. Stephenson, Jasmine B. Ayers, Hoda Safari Yazd, Megan R. Miller, John A. Lednicky, Rhoel R. Dinglasan · 2023 · Frontiers in Microbiology
60. Tratamiento farmacológico para COVID-19 en protocolos latinoamericanos: Una revisión narrativa de la eficacia y seguridad
    Centro Brasileiro de Informação sobre Medicamentos, Conselho Federal de Farmácia. Brasília, DF, Brasil, Pamela Alejandra Escalante Saavedra, Martín Cañás, CIMEFF Área de Farmacología, Federación Médica de la Provincia de Buenos Aires (FEMEBA), La Plata, Argentina, Dulce María Calvo Barbado, Asesora independiente, Barcelona, España, Liliana Barajas Esparza, Instituto de Ciencias de la Salud, Universidad Autónoma del Estado de Hidalgo, Pachuca de Soto, Hidalgo, México, Mariana Caffaratti, Centro de Información de Medicamentos, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Córdoba, Argentina et al. · 2020
61. COVID-19: Epidemiologische und klinische Fakten
    Christoph Josef Hemmer, Hilte Friederike Geerdes-Fenge, Emil Christian Reisinger · 2020 · Der Radiologe
62. Glucose-6-phosphate dehydrogenase deficiency and SARS-CoV-2 mortality: Is there a link and what should we do?
    Seyed Fazel Nabavi, Solomon Habtemariam, Antoni Sureda, Maciej Banach, Ioana Berindan‐Neagoe, Cosmin Andrei Cismaru, Mahdi Bagheri, Mohammad Sadegh Bagheri, Seyed Mohammad Nabavi · 2020 · Clinical Biochemistry
63. Management of Coronavirus Disease 2019 (COVID‐19) Pandemic: From Diagnosis to Treatment Strategies
    Zhina Hadisi, Tavia Walsh, Seyed Mohammad Hossein Dabiri, Amir Seyfoori, David Hamdi, Bahram Mirani, Erik Pagan, Armando Jardim, Mohsen Akbari · 2020 · Advanced Therapeutics
64. Effects of chloroquine or hydroxychloroquine treatment on non‐SARS‐CoV2 viral infections: A systematic review of clinical studies
    Xizhong Cui, Junfeng Sun, Samuel J. Minkove, Yan Li, Diane Cooper, Zoe G. Couse, Peter Q. Eichacker, Parizad Torabi‐Parizi · 2021 · Reviews in Medical Virology
65. COVID-19 desde una perspectiva cardiovascular
    Alfonso Bryce, Mayte Bryce‐Alberti, Arianna Portmann-Baracco, Juan Urquiaga-Calderón, César Antonio Larrauri Vigna, Edmundo Alegría Valdivia · 2020 · Archivos de cardiología de México
66. In silico Exploration of Interactions Between Potential COVID-19 Antiviral Treatments and the Pore of the hERG Potassium Channel—A Drug Antitarget
    Ehab Al‐Moubarak, Mohsen Sharifi, Jules C. Hancox · 2021 · Frontiers in Cardiovascular Medicine
67. Antimalarial drugs—are they beneficial in rheumatic and viral diseases?—considerations in COVID-19 pandemic
    Bogna Grygiel‐Górniak · 2021 · Clinical Rheumatology
68. Association Between US Administration Endorsement of Hydroxychloroquine for COVID-19 and Outpatient Prescribing
    James J Harrigan, Rebecca A. Hubbard, Sunil Thomas, Ralph J. Riello, Erin Mary Bange, Mira Mamtani, Ronac Mamtani · 2020 · Journal of General Internal Medicine
69. Actualización de la Declaración de consenso en medicina critica para la atención multidisciplinaria del paciente con sospecha o confirmación diagnóstica de COVID-19
    J.L. Mendoza, Víctor Hugo Nieto Estrada, Nelly Beltrán López, Elisabeth Ramos Bolaños, Daniel Molano Franco, Carmelo Rafael Dueñas Castell, Albert Alexander Valencia Moreno, Iván Amaya, John Serna Flórez, BLADIMIR ALEJANDRO GIL VALENCIA et al. · 2020 · Acta Colombiana de Cuidado Intensivo
70. Serious Adverse Events Associated With Hydroxychloroquine Amidst COVID-19 Pandemic: Case Series and Literature Review
    Ramy Abdelmaseih, Randa Abdelmasih, Mustajab Hasan, Srikanth Tadepalli, Jigar Patel · 2020 · Cureus
71. Comparison of Cell Fusions Induced by Influenza Virus and SARS-CoV-2
    Chuyuan Zhang, Xin-Jie Meng, Han-Jun Zhao · 2022 · International Journal of Molecular Sciences
72. Enhanced Epistemic Trust and the Value-Free Ideal as a Social Indicator of Trust
    T. Y. Branch · 2022 · Social Epistemology
73. Plasma from donors convalescent from SARS-CoV-2 infection–A matter of priorities
    Albert Farrugia · 2020 · Transfusion Clinique et Biologique
74. The Hypothetical Role of Erythrocytes in COVID-19: Immediate Clinical Therapy
    R Ansovini, Laura Compagnucci · 2020 · Journal of Biomedical Research & Environmental Sciences
75. Cardiovascular Considerations in Coronavirus Disease 2019 with a Special Focus on Arrhythmia
    Tiffany Ying Hu, Justin Lee, Samuel J. Asirvatham · 2020 · Journal of Innovations in Cardiac Rhythm Management
76. Anti-rheumatic drugs as potential anti-inflammatory, immunomodulatory agents against COVID-19: A systematic review
    Reza Sinaei, Sara Pezeshki, Ali Asadipour, Reza Shiari, Roya Sinaei, Ali Sinaei · 2021 · Pharmaceutical Sciences
77. Protocol-based cardiotoxicity monitoring in hydroxychloroquine medicated COVID-19 pediatric patients
    Inês Hormigo, Tiago Milheiro Silva, Sérgio Matoso Laranjo, Conceição Trigo, Ana Margarida Garcia, Catarina Gouveia, Maria João Brito · 2021 · Revista Portuguesa de Cardiologia
78. QTc prolongation in patients with COVID-19: a retrospective chart review
    Suphannika Prateepjarassaeng Pornwattanakavee, Watcharapong Priksri, Nattawut Leelakanok · 2021 · Translational and Clinical Pharmacology
79. Challenges for the practice of evidence-based medicine during COVID-19 pandemic (practice of evidence-based medicine in the new normal)
    PremanathFakirayya Kotur, Pushpa Premanath Kotur · 2022 · Indian Journal of Anaesthesia
80. Use of combined treatment of 3rd-generation cephalosporin, azithromycin and antiviral agents on moderate SARs-CoV-2 patients in South Korea: A retrospective cohort study
    Wooyoung Hong, Yukyung Park, Bong-Ok Kim, Sung Kyu Park, Jiin Shin, Soon-Pyo Jang, Hea-Woon Park, Wonjong Yang, Joonyoung Jang, Soon-Woo Jang et al. · 2022 · PLoS ONE
81. Myth surrounding the FDA disapproval of hydroxychloroquine sulfate and chloroquine phosphate as drugs for coronavirus disease 2019
    Chukwuebuka Egbuna, Subhash Chandra, Chinaza Godswill Awuchi, Sarla Saklani, Ihtisham Ul Haq, Muhammad Akram, Kingsley Chukwuemeka Patrick-Iwuanyanwu, Johra Khan · 2022 · Elsevier eBooks
82. Progress, pitfalls, and path forward of drug repurposing for COVID-19 treatment
    Noha Samir Taibe, Maimona A. Kord, Mohamed A. Badawy, Iart Luca Shytaj, Mahmoud ElHefnawi · 2022 · Therapeutic Advances in Respiratory Disease
83. A “war on science?” Far-right movements and the disputes over epistemic authority in Brazil
    Daniel Edler Duarte, Pedro Rolo Benetti, Marcos César Alvarez · 2024 · Tapuya Latin American Science Technology and Society
84. A Comprehensive Analysis of Clinical Trials in the COVID-19 Pandemic Era
    Jinhee Lee, Han Wul Shin, Jun Young Lee, Jae Seok Kim, Jae Won Yang, Keum Hwa Lee, Andreas Kronbichler, Jae Il Shin · 2020 · Medicina
85. How COVID-19 Affects Patients Receivingc anticytokine and JAK Inhibitors in Rheumatology and Dermatology
    Ting Yi Jessica Chang, Janet Elizabeth Pope · 2020 · Immunotherapy
86. An Updated Systematic Review and Network Meta-Analysis of 25 Randomized Trials Assessing the Efficacy and Safety of Treatments in Covid-19 Disease
    Alhassane Diallo, Miguel Carlos‐Bolumbu, Traoré Marie, Mamadou Diallo, Christophe Jedrecy · 2021 · Journal of Public Health Research
87. Covid-19 pandemic: Perspectives on management
    Prem Gathiram, Jagidesa Moodley, Olive Pearl Khaliq · 2021 · Journal of Reproductive Immunology
88. Hydroxychloroquine/chloroquine in patients with COVID-19 in Wuhan, China: a retrospective cohort study
    Zhe Chen, Aihua Liu, Yongjing Cheng, Xutao Wang, Xiaomao Xu, Jia Huang, Yuqing Ma, Ming Li Gao, Cibo Huang · 2021 · BMC Infectious Diseases
89. Prevalence of comorbid tuberculosis amongst COVID‐19 patients: A rapid review and meta‐analysis
    Yadong Wang, Jie Xu, Ying Wang, Hongjie Hou, Li Shi, Haiyan Yang · 2021 · International Journal of Clinical Practice
90. Clinical Evidence Informing Treatment Guidelines on Repurposed Drugs for Hospitalized Patients During the Early COVID-19 Pandemic: Corticosteroids, Anticoagulants, (Hydroxy)chloroquine
    Stefanie Wüstner, Sara Hogger, Daniela Gartner-Freyer, Andrea Lebioda, Katharina Schley, Friedhelm Leverkus · 2022 · Frontiers in Public Health
91. Could Preventing Thromboembolism be a New Hope for COVID-19 Patients?
    Marcos Roberto Tovani‐Palone, Lorenzo Storari, Valerio Barbari · 2020 · Electronic Journal of General Medicine
92. Less is more, now more than ever
    Christine Soong, Karen B. Born, Wendy S. Levinson · 2020 · BMJ Quality & Safety
93. Tratamento precoce para COVID-19 baseado em evidência científica
    Sabas Carlos Vieira, Danilo Rafael da Silva Fontinele, Marina Bucar Barjud, Justino Moreira de Carvalho, Lina Madeira Campos Melo, José Wilson Fonseca Filho, Gérson Luís Medina Prado, Alexandre Adad Alencar · 2020 · Revista Brasileira em Promoção da saúde
94. Exploring insights of hydroxychloroquine, a controversial drug in Covid-19: An update
    Gaurav Joshi, Shikha Thakur, Mayank Mayank, Poduri Ramarao · 2021 · Food and Chemical Toxicology
95. Review of Pharmacotherapy Trialed for Management of the Coronavirus Disease-19
    Kimberly Hall, FUHBE MFONE, Michael Shallcross, Vikas Pathak · 2021 · Eurasian Journal of Medicine
96. Cellular immunotherapy for COVID-19-induced acute respiratory distress syndrome: Results of the CIRCA-19 phase 1 safety and phase 2 randomized controlled trials
    Shane W. English, Dean A. Fergusson, Manoj Mathew Lalu, David W. Courtman, Saad Khan, Mohamad Sobh, Irene Watpool, Josée Champagne, Samantha Hodgins, Bernard Thébaud et al. · 2026 · Stem Cell Reports
97. HYDROXYCHLOROQUINE AND AZITHROMYCIN COMBINATION COULD BE LETHAL TO COVID-19 PATIENTS
    Sayeed Mohammed Firdous · 2020 · FARMACIA
98. Arrhythmogenesis and COVID-19
    John N. Varkey, William H. Frishman · 2021 · Cardiology in Review
99. Antigen-Specific Antibody Signature Is Associated with COVID-19 Outcome
    Bárbara Batista Salgado, Maele Ferreira Jordão, Thiago Barros do Nascimento de Morais, Danielle Severino Sena da Silva, Ivanildo Vieira Pereira Filho, Wlademir Braga Salgado Sobrinho, Nani Oliveira Carvalho, Rafaella Oliveira dos Santos, Julia Forato, Priscilla Paschoal Barbosa et al. · 2023 · Viruses
100. Efficacy and safety of in-hospital treatment of Covid-19 infection with low-dose hydroxychloroquine and azithromycin in hospitalized patients: A retrospective controlled cohort study
     Gert Meeus, Frauke Van Coile, Hans Pottel, Ann-Sophie Michel, Ortwin Vergauwen, Katy Verhelle, Stoffel Lamote, Mathias Leys, Michaël Boudewijns, Pieter Samaey · 2023 · New Microbes and New Infections